Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Non-Current Assets (2016 - 2025)

Haemonetics has reported Non-Current Assets over the past 16 years, most recently at $1.5 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 1.43% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $6.2 billion, up 1.16%, while the annual FY2025 figure was $1.5 billion, 6.26% up from the prior year.
  • Non-Current Assets for Q4 2025 was $1.5 billion at Haemonetics, roughly flat from $1.5 billion in the prior quarter.
  • Over five years, Non-Current Assets peaked at $1.6 billion in Q3 2024 and troughed at $1.1 billion in Q1 2022.
  • A 5-year average of $1.3 billion and a median of $1.2 billion in 2022 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 69.77% in 2021 and later fell 2.01% in 2022.
  • Year by year, Non-Current Assets stood at $1.1 billion in 2021, then increased by 6.31% to $1.2 billion in 2022, then grew by 22.5% to $1.4 billion in 2023, then grew by 6.27% to $1.5 billion in 2024, then grew by 1.43% to $1.5 billion in 2025.
  • Business Quant data shows Non-Current Assets for HAE at $1.5 billion in Q4 2025, $1.5 billion in Q3 2025, and $1.5 billion in Q2 2025.